

Cdk2/Cyclin Inhibitory Peptide II

Cat. No.:	HY-P3731	
CAS No.:	237392-85-7	
Molecular Formula:	$C_{110}H_{200}N_{48}O_{25}$	
Molecular Weight:	2595.07	YGRKKRRQRRRGPVKRRDL
Sequence Shortening:	YGRKKRRQRRRGPVKRRDL	
Target:	CDK	
Pathway:	Cell Cycle/DNA Damage	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	

BIOLOGICAL ACTIVITY

Description	Cdk2/Cyclin Inhibitory Peptide II (Tat-LDL), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner ^[1] .	
IC ₅₀ & Target	CDK ^[1] .	
In Vitro	Cdk2/Cyclin Inhibitory Peptide II (0-150 µM; 24 h) kills U2OS osteosarcoma cells in a dose-dependent manner ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay ^[1]	
	Cell Line:	U2OS osteosarcoma cells
	Concentration:	0-150 µM
	Incubation Time:	24 h
	Result:	Exhibited good activity to kill U2OS osteosarcoma cells.

REFERENCES

[1]. Chen YN, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4325-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA